Literature DB >> 22476407

Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo.

Xiaocai Yan1, Kara Doffek, Chaobo Yin, Michael Krein, Michael Phillips, Sonia L Sugg, Bryon Johnson, Joel Shilyansky.   

Abstract

The goal of the current study is to determine the effects of blocking phosphatidylserine (PS) on the growth of neuroblastoma in mice. PS, an anionic phospholipid restricted to the cytoplasmic surface of plasma membranes in most cells, is externalized to the surface of apoptotic cells. PS has been shown to induce immune tolerance to self-antigens. PS can also be found on the surface of live cells and in particular tumor cells. Annexin-V (AnV) is a protein that specifically binds and blocks PS. To determine the effects of blocking PS with AnV on tumor growth and immunogenicity, mice were inoculated with AGN2a, a poorly immunogenic murine neuroblastoma that expresses high level of PS on the cell surface. Survival and anti-tumor T cell response were determined. AGN2a were engineered to secrete AnV. Secreted protein effectively blocked tumor PS. 40 % of mice inoculated with AnV-expressing AGN2a cells survived free of tumor, whereas none of the mice inoculated with control cells survived (p = 0.0062). The benefits of AnV were lost when mice were depleted of T cells. The findings suggest that AnV could protect mice from tumor challenge through an immune mediated mechanism. Mice were then immunized with irradiated AnV-secreting or control cells, and challenged with wild-type AGN2a cells. AnV-secreting cell vaccine protected 80 % of mice from AGN2a challenge, while control cell vaccine prevented tumor growth in only 30 % of animals (p = 0.012). ELISPOT analysis demonstrated that AnV-secreting cell vaccine induced a greater frequency of interferon-gamma producing splenic T cells. T cells isolated from mice immunized with AnV-secreting but not control vaccine lysed AGN2a. In summary, AnV blocked PS, enhanced T cell mediated tumor immunity, and inhibited tumor growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476407     DOI: 10.1007/s00262-012-1250-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Annexin V incorporated into influenza virus particles inhibits gamma interferon signaling and promotes viral replication.

Authors:  Fatma Berri; Ghina Haffar; Vuong Ba Lê; Anne Sadewasser; Katharina Paki; Bruno Lina; Thorsten Wolff; Béatrice Riteau
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

2.  Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.

Authors:  Bruce D Freimark; Jian Gong; Dan Ye; Michael J Gray; Van Nguyen; Shen Yin; Michaela M S Hatch; Christopher C W Hughes; Alan J Schroit; Jeff T Hutchins; Rolf A Brekken; Xianming Huang
Journal:  Cancer Immunol Res       Date:  2016-04-04       Impact factor: 11.151

Review 3.  The clearance of dead cells by efferocytosis.

Authors:  Emilio Boada-Romero; Jennifer Martinez; Bradlee L Heckmann; Douglas R Green
Journal:  Nat Rev Mol Cell Biol       Date:  2020-04-06       Impact factor: 94.444

4.  AnnexinA5 Might Suppress the Phenotype of Human Gastric Cancer Cells via ERK Pathway.

Authors:  Xiaojie Wang; Yarui Dai; Yina Zhao; Meichuan Li; Jialu Zhang; Yunzhe Ci; Huan Wang; Xin Li
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

5.  Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.

Authors:  Michael J Gray; Jian Gong; Michaela M S Hatch; Van Nguyen; Christopher C W Hughes; Jeff T Hutchins; Bruce D Freimark
Journal:  Breast Cancer Res       Date:  2016-05-11       Impact factor: 6.466

6.  Promotion of HepG2 cell apoptosis by flower of Allium atroviolaceum and the mechanism of action.

Authors:  S Khazaei; R Abdul Hamid; N Mohd Esa; V Ramachandran; Ghomi Tabatabaee F Aalam; A Etemad; P Ismail
Journal:  BMC Complement Altern Med       Date:  2017-02-10       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.